These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 33993741)

  • 1. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
    Signorelli C; Gemma D; Grande R; DE Marco S; Saltarelli R; Morandi MG; Spinelli GP; Zoratto F; Sperduti I; Chilelli MG; Ceribelli A; Ruggeri EM
    Anticancer Res; 2021 May; 41(5):2553-2561. PubMed ID: 33952483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
    Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
    Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
    Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
    PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness.
    Giuliani J; Fiorica F; Ponturo G; Azzurro M; Ruzzenente A; Bonetti A
    J Oncol Pharm Pract; 2021 Jun; 27(4):974-977. PubMed ID: 33541208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer.
    Barone C; Bartolomeo MD; Lonardi S; Maiello E; Martinelli E; Moretto R; Strippoli A; Tamburini E; Zaniboni A; Pinto C
    Future Oncol; 2021 May; 17(14):1749-1759. PubMed ID: 33464133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.
    Patel AK; Duh MS; Barghout V; Yenikomshian MA; Xiao Y; Wynant W; Tabesh M; Fuchs CS
    Clin Colorectal Cancer; 2018 Sep; 17(3):e531-e539. PubMed ID: 29803544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Regorafenib vs. Trifluridine/Tipiracil in Unresectable Colorectal Cancer: A Retrospective Cohort Study.
    Nakashima M; Takeuchi M; Kawakami K
    Clin Colorectal Cancer; 2020 Dec; 19(4):e208-e225. PubMed ID: 32912821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
    Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
    Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
    Coutzac C; Trouilloud I; Artru P; Henriques J; Masson T; Doat S; Bouché O; Coriat R; Saint A; Moulin V; Vernerey D; Gallois C; De La Fouchardière C; Tougeron D; Taieb J
    Clin Colorectal Cancer; 2022 Jun; 21(2):132-140. PubMed ID: 35337742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 14. A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer.
    Cecchini M; Kortmansky JS; Cui C; Wei W; Thumar JR; Uboha NV; Hafez N; Lacy J; Fischbach NA; Sabbath KD; Gomez CM; Sporn JR; Stein S; Hochster HS
    Cancer; 2021 May; 127(9):1417-1424. PubMed ID: 33351187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
    Suenaga M; Wakatsuki T; Mashima T; Ogura M; Ichimura T; Shinozaki E; Nakayama I; Osumi H; Ota Y; Takahari D; Chin K; Seimiya H; Yamaguchi K
    Invest New Drugs; 2020 Feb; 38(1):111-119. PubMed ID: 30838483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
    Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
    Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
    Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
    Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
    Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
    Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.